P398: Disease clearance: a potential target for management of patients with Ulcerative ColitisECCO’23 CopenhagenYear: 2023
Authors: Andronic, A.M.(1)*;Toader, E.(1);
(1)"Grigore T. Popa" University of Medicine and Pharmacy, Institute of Gastroenterology and Hepatology, Iasi, Romania;
P399: Detection of iron restricted erythropoiesis in patients with IBD: How can we disentangle effects of inflammation?ECCO’23 CopenhagenYear: 2023
Authors: Aksan, A.(1,2,3)*;Mangold, C.(4);Stötzel, J.(1,3);Tessmer, L.(3,5);Schröder, O.(3,5);Stein, J.M.(3,5,6);
(1)Justus-Liebig University Giessen, Institute of Nutritional Science, Giessen, Germany;(2)Immundiagnostik AG, Medical Affairs, Bensheim, Germany;(3)Interdisciplinary Crohn-Colitis Centre Rhein-Main, Clinical Research, Frankfurt am Main, Germany;(4)Goethe University Frankfurt, Faculty of Medicine, Frankfurt am Main, Germany;(5)DGD Clinics Sachsenhausen, Gastroenterology/Oncology, Frankfurt am Main, Germany;(6)Goethe University Frankfurt, Institute of Pharmaceutical Chemistry, Frankfurt am Main, Germany;
P400: Identifying Nutritional targets in Crohn's disease: INTICO1: a time-limited trial of exclusive enteral nutrition during adult CD remissionECCO’23 CopenhagenYear: 2023
Authors: McDonnell, M.(1,2)*;Westoby, C.(3);Sartain , S.(1);Giannasca, P.(4);Corthésy, J.(5);Grzywinski, Y.(6);Frézal, A.(5);Capt, P.(5);Cummings, F.(1);Wootton, S.(7);
(1)University Hospital Southampton, Gastroenterology, Southampton, United Kingdom;(2)University of Southampton, Faculty of Medicine, Southampton, United Kingdom;(3)University Hospital Southampton, Department of Nutrition and Dietetics, Southampton, United Kingdom;(4)Nestle Health Science, Nestle Research, Cambridge, United States;(5)EPFL Innovation Park, Nestlé Research- Société des Produits Nestlé S.A, Lausanne, Switzerland;(6)EPFL Innovation Park, Nestlé Research- Société des Produits Nestlé S.A, Lasuanne, Switzerland;(7)University Hospital Southampton, Human Nutrition, Southampton, United Kingdom;
P401: Concomitant azathioprine treatment effects vedolizumab treatment persistence in Crohn's Disease but not in Ulcerative ColitisECCO’23 CopenhagenYear: 2023
Authors: Toruner, M.(1)*;Guvenir, T.(1);Er, R.E.(1);Soykan, I.(1);
(1)Ankara University School of Medicine, Department of Gastroenterology, Ankara, Turkey;
P402: A Pilot Study on the Effect of Colesevelam on the Microbiome in Primary Terminal Ileal Resected Crohn's DiseaseECCO’23 CopenhagenYear: 2023
Authors: Kumar, A.(1)*;Quraishi, M.N.(2);Al-Hassi, H.O.(3);Elasrag, M.(4);Segal, J.P.(5);Jain, M.(1);Steed, H.(1);Butterworth, J.(6);Farmer, A.(7);McLaughlin, J.(8);Beggs, A.(4);Brookes, M.(1);
(1)The Royal Wolverhampton NHS Trust, Department of Gastroenterology, Wolverhampton, United Kingdom;(2)University Hospitals Birmingham NHS Foundation Trust, Department of Gastroenterology, Birmingham, United Kingdom;(3)University of Wolverhampton, Faculty of Sciences and Engineering, Wolverhampton, United Kingdom;(4)University of Birmingham, Institute of Cancer and Genomic Sciences, Birmingham, United Kingdom;(5)Northern Hospital, Department of Gastroenterology, Victoria, Australia;(6)Shrewsbury and Telford Hospital NHS Trust, Department of Gastroenterology, Shrewsbury, United Kingdom;(7)University Hospitals of North Midlands, Department of Gastroenterology, Stoke-on-Trent, United Kingdom;(8)Salford Royal Foundation Trust, Department of Gastroenterology, Salford, United Kingdom;
P403: Therapeutic compliance in patients with chronic inflammatory bowel disease.ECCO’23 CopenhagenYear: 2023
Authors: Hajlaoui, A.(1)*;Sabbah, M.(2);Bibani, N.(2);Jlassi, H.(2);Bellil , N.(2);Lassoued, K.(2);Trad, D.(2);Gargouri, D.(2);
(1)Habib Thameur Hospital, Department of gastroenterology., tunis, Tunisia;(2)Habib thameur hospital, Department of gastroenterology, tunis, Tunisia;
P404: Persistence of subcutaneous infliximab after switching from intravenous in a French national cohort of IBD patients in remissionECCO’23 CopenhagenYear: 2023
Authors: Mathieu, N.(1)*;Riviere, P.(2); Heluwaert, F.(3); Hébuterne, X.(4);Chupin, A.(5);Bouguen, G.(6);Vuitton, L.(7);Allez, M.(8);Montuclard, C.(9);Nachury, M.(10);Nancey, S.(11);Amélie, B.(12); Gilletta, C.(13);Abitbol, V.(14);Altwegg, R.(15);de Maissin, A.(16);Plastaras , L.(17); Ah Soune, P.(18);Boureille, A.(19);Bouhnik, Y.(20);Seksik, P.(21);Chanteloup, E.(22);marion, S.(23);Uzzan, M.(24);Andrau, P.(25);Rouillon, C.(26);Arondel, Y.(27);Peyrin Biroulet, L.(28);Laharie, D.(29);
(1)CHU Grenoble Alpes, Hepato-gastroenterology and digestive oncology department- University Hospital, Grenoble, France;(2)University Hospital of Bordeaux, Department of Gastroenterology, Bordeaux, France;(3)University Hospital of Nimes- Nimes- France, Department of Gastroenterology-, Annecy, France;(4)CHU of Nice- University Côte d'Azur-, Gastroenterology and Clinical Nutrition-, Nice, France;(5)Assistance publique-Hôpitaux de Paris AP-HP, Service de Gastro-Entérologie-, Paris, France;(6)CHU Rennes- Univ Rennes- INSERM- CIC1414- Institut NUMECAN Nutrition Metabolisms and Cancer-, Department of Gastroenterology, Rennes, France;(7)University Hospital of Besançon, Department of Gastroenterology, Besançon, France;(8)Assistance publique-Hôpitaux de Paris AP-HP- Hopital St-Louis, Service de Gastro-Entérologie-, Paris, France;(9)Valence Hospital, Department of Gastroenterology, Valence, France;(10)Institute for Translational Research in Inflammation, Universitéde Lille- Inserm- CHU Lille- U1286 - INFINITE, Lille, France;(11)Inserm U1111-CIRI- Lyon-Sud University Hospital- Hospices Civils de Lyon, Department of Gastroenterology-, Lyon, France;(12)Reims University Hospital, Department of Gastroenterology, Reims, France;(13)Toulouse University Hospital, Department of Gastroenterology, Toulouse, France;(14)Assistance publique-Hôpitaux de Paris AP-HP- Cochin Hospital, Service de Gastro-Entérologie-, Paris, France;(15)University Hospital of Montpellier, Department of Gastroenterology-, Montpellier, France;(16)CHD la Roche sur Yon Hospital, Department of gastroenterology, La Roche sur Yon, France;(17)Colmar Hospital, Department of Gastroenterology- University Hospital of Nimes, Colmar, France;(18)Toulon Hospital, Department of gastroenterology, Toulon, France;(19)Nantes University Hospital, Department of Gastroenterology, Nantes, France;(20)groupe hospitalier Ambroise Paré - Hartmann, institut des MICI, Paris, France;(21)Centre de recherche Saint-Antoine- Sorbonne Université- INSERM- APHP- Hôpital Saint-Antoine, Department of Gastroenterology, Paris, France;(22)Groupe hospitalier Saint Joseph, Depatment of gastroenterology, Paris, France;(23)Institut mutualiste Montsouris IMM, department of gastroenterology, Paris, France;(24)Beaujon Hospital- APHP- Clichy, Department of Gastroenterology, Paris, France;(25)Tarbes Hospital, Department of Gastroenterology, Tarbes, France;(26)Caen University Hospital, Department of Gastroenterology-, Caen, France;(27)centre hospitalier de Haguenau, Department of gastroenterology, Haguenau, France;(28)University Hospital of Nancy- University of Lorraine, Department of Gastroenterology and INSERM NGERE U1256, Vandoeuvre-lès-Nancy, France;(29)CHU de Bordeaux- Hôpital Haut-Lévêque-, Service d'Hépato-gastroentérologie et oncologie digestive –Universitéde Bordeaux, Bordeaux, France;
P405: Long-term safety of 3 years of ozanimod in moderately to severely active ulcerative colitis: an interim analysis of the True North open-label extensionECCO’23 CopenhagenYear: 2023
Authors: Panaccione, R.(1)*;Danese, S.(2);Wolf, D.C.(3);Canavan, J.B.(4);Jain, A.(4);Wu, H.(4);Petersen, A.(4);Charles, L.(4);Afzali, A.(5);Abreu, M.T.(6);
(1)Inflammatory Bowel Disease Clinic, Medicine, Calgary, Canada;(2)IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Gastroenterology and Endoscopy, Milan, Italy;(3)Atlanta Gastroenterology Associates LLC, Medicine, Atlanta, United States;(4)Bristol Myers Squibb, Clinical Research, Princeton, United States;(5)University of Cincinnati, Division of Digestive Diseases, Cincinnati, United States;(6)The University of Miami Miller School of Medicine, Medicine, Miami, United States;
P406: Observational study of the effectiveness of vedolizumab on treatment outcomes and health-related quality of life in biologic-naïve patients with Inflammatory Bowel Diseases in Greece – the TROVE study - Interim AnalysisECCO’23 CopenhagenYear: 2023
Authors: Chatzinikolaou-, M.L.(1)*;Kifnidi, C.(2);Kokkotis, G.(1);Gatopoulou, A.(3);Michopoulos, S.(4);Soufleris, K.(5);Poulopoulos, G.(6);Theodoropoulou, A.(7);Mantzaris, G.(8);Ntelis, V.(9);Papatheodoridis, G.(10);Tzouvala, M.(11);Koutroubakis, I.E.(12);Theocharis, G.(13);Kourikou, A.(14);Christodoulou, D.(15);Grammatopoulos, A.(16);Michalopoulos, G.(17);Georgopoulos, S.(18);Akriviadis, E.(19);Vradelis, S.(20);Gkagkari, V.(4);Zampeli, E.(4);Fasoulas, K.(5);Charalampidis, M.(6);Velegraki, M.(7);Karampekos, G.(8);Viazis, N.(8);Andrianakou , G.(9);Karatzas, P.(10);Tribonias, G.(11);Zacharopoulou, E.(11);Orfanoudaki, E.(12);Tsellou, E.(2);Psyrilos, A.(2);Roussou, D.(2);Bamias, G.(1);
(1)National and Kapodistrian University of Athens- Sotiria Hospital, GI Unit- 3rd Department of Internal Medicine, Athens, Greece;(2)Takeda Hellas SA, Medical Department, Athens, Greece;(3)University Hospital of Alexandroupolis, 2nd Dept of Internal Medicine, Alexandroupolis, Greece;(4)Alexandra Hospital, GI Unit, Athens, Greece;(5)Theageneio Anticancer Hospital, Gastroenterology Department, Thessaloniki, Greece;(6)Private Practice, GI Unit, Thessaloniki, Greece;(7)Venizeleio General Hospital, Gastroenterology Department, Heraklion, Greece;(8)GHA “Evangelismos-Polykliniki” General Hospital, Gastroenterology Department, Athens, Greece;(9)“G. Gennimatas” General Hospital, Gastroenterology Department, Athens, Greece;(10)Medical School of National and Kapodistrian University of Athens- “Laikon” General Hospital, Academic Dept of Gastroenterology, Athens, Greece;(11)“Agios Panteleimon” General Hospital Nikaia-Piraeus, Gastroenterology Department, Nikaia, Greece;(12)University Hospital of Heraklion, Gastroenterology Department, Heraklion, Greece;(13)University Hospital of Patras, Gastroenterology Department, Patras, Greece;(14)Medical School- National and Kapodistrian University of Athens- Hippocration Hospital, 2nd Academic Dept of Internal Medicine- GI-Liver- Endoscopy Unit, Athens, Greece;(15)University Hospital of Ioannina, Gastroenterology Department, Ioannina, Greece;(16)“Metropolitan” Hospital, Gastroenterology Department, Faliro, Greece;(17)“Tzaneion”- General Hospital of Piraeus, Gastroenterology Department, PIraeus, Greece;(18)Athens Medical Group - Faliron, Gastroenterology Department, Faliro, Greece;(19)“Hippokratio” General Hospital of Thess., Gastroenterology Department, Thessaloniki, Greece;(20)University Hospital of Thrace, Gastroenterology Department, Alexandroupolis, Greece;
P407: Efficacy and safety of etrasimod in subjects with moderately to severely active isolated proctitis: a subgroup analysis of the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trialsECCO’23 CopenhagenYear: 2023
Authors: Peyrin-Biroulet, L.(1,2)*;Dubinsky, M.C.(3);Sands, B.E.(4);Panés, J.(5);Schreiber, S.(6);Reinisch, W.(7);Feagan, B.G.(8);Danese, S.(9);Yarur, A.(10);D'Haens, G.(11);Goetsch, M.(12);Wosik, K.(13);Wu, J.(14);Modesto, I.(15);McDonnell, A.(16);Bartolome, L.(17);Rabbat, C.J.(18);Vermeire, S.(19);
(1)University of Lorraine- Inserm- NGERE, Gastroenterology, Nancy, France;(2)Groupe Hospitalier privé Ambroise Paré - Hartmann, Paris IBD Center, Neuilly sur Seine, France;(3)Feinstein IBD Center- Icahn School of Medicine, Gastroenterology, New York- New York, United States;(4)Icahn School of Medicine at Mount Sinai, Dr. Henry D. Janowitz Division of Gastroenterology, New York- New York, United States;(5)Hospital Clínic de Barcelona- IDIBAPS- CIBERehd, Gastroenterology, Barcelona, Spain;(6)Kiel University, University Hospital Schleswig-Holstein- Department Internal Medicine I, Kiel, Germany;(7)Medical University of Vienna, Department of Internal Medicine III- Division Gastroenterology and Hepatology, Vienna, Austria;(8)University of Western Ontario/Alimentiv Inc, Gastroenterology, London- Ontario, Canada;(9)IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Gastroenterology, Milan, Italy;(10)Cedars-Sinai Medical Center, Gastroenterology, Los Angeles- California, United States;(11)University of Amsterdam, Gastroenterology, Amsterdam, The Netherlands;(12)Pfizer AG, Global Clinical Development, Zurich, Switzerland;(13)Pfizer Inc, Global Medical Affairs- Gastroenterology, Kirkland- Quebec, Canada;(14)Pfizer Inc, Global Product Development, Groton- Connecticut, United States;(15)Pfizer Inc, Global Medical Affairs- Gastroenterology, Madrid, Spain;(16)Pfizer- Ltd, Safety Risk, Walton Oaks- Scurry, United Kingdom;(17)Pfizer Inc, Global Health Economics & Outcomes Research- Inflammation & Immunology, New York- New York, United States;(18)Pfizer Inc, Global Medical Affairs- Gastroenterology, New York- New York, United States;(19)University Hospitals Leuven, Gastroenterology, Leuven, Belgium;
P408: Dual therapy with vedolizumab and tofacitinib in refractory ulcerative colitis patients – single centre experienceECCO’23 CopenhagenYear: 2023
Authors: Kolar, M.(1);Kastylova, K.(1);Lukas, M.(1);Duricova, D.(1);Hruba, V.(1);Machkova, N.(1);Cerna, K.(1);Jirsa, J.(1);Kubickova, K.(1);Vojtechova, G.(1);Lukás, M.(1)*;
(1)ISCARE a.s., IBD Clinical and Research Center, Prague, Czech Republic;
P409: Using antidepressants for refractory symptoms of Inflammatory Bowel Disease: a prospective service evaluationECCO’23 CopenhagenYear: 2023
Authors: Moulton, C.(1)*;Avery, P.(2);Hart, A.(3);
(1)St Mark's Hospital, Psychological Medicine Unit, London, United Kingdom;(2)St Mark's Hospital, Inflammatory Bowel Disease Nursing Team, London, United Kingdom;(3)St Mark's Hospital, St Mark's Academic Institute, London, United Kingdom;
P410: Long-term persistence and safety of biological drugs in patients with Inflammatory Bowel Disease. Differences between women and men: SEXEII study of ENEIDAECCO’23 CopenhagenYear: 2023
Authors: Gargallo-Puyuelo, C.(1)*;Ricard, E.(2);Iborra, M.(3);Iglesias-Flores, E.(4);Vera Mendoza, I.(5);De Francisco García, R.(6);Calafat Sard, M.(7);Minguez, M.(8);Lopez- San Roman, A.(9);Taxonera, C.(10);Guardiola, J.(11);Barrio, J.(12);Laredo, V.(13);De Castro, L.(14);Gisbert, J.(15);García-Lopez, S.(16);García Planella, E.(17);Martín Arranz, D.(18);Calvet, X.(19);Merino, O.(20);Sierra, M.(21);Marquez, L.(22);Madero, L.(23);Varela, P.(24);Carpio, D.(25);Esteve, M.(26);Rivero, M.(27);Ramos , L.(28);Sicilia, B.(29);Lorente POyatos, R.(30);Marin, I.(31);Monfort, D.(32);Navarro, M.(33);VEga, P.(34);Hinojosa, J.(35);Tardillo, C.(36);García Sepulcre, M.F.(37);Barreiro, M.(38);Domenech, E.(7);Gomollón, F.(39);
(1)Hospital Clínico Universitario Lozano Blesa, Gastroenterology., Zaragoza, Spain;(2)H. Clínic Barcelona, Gastroenterology, Barcelona, Spain;(3)Hospital Universitario La Fe de Valencia, Gastroenterology, Valencia, Spain;(4)H. Reina Sofía, Gastroenterology, Cordoba, Spain;(5)H.U. Puerta de Hierro, Gastroenterology, Madrid, Spain;(6)Hospital Universitario Central de Asturias, Gastroenterology, Oviedo, Spain;(7)H.U. Germans Trias i Pujol, Gastroenterology, Barcelona, Spain;(8)H. Clínico de Valencia, Gastroenterology, Valencia, Spain;(9)H. Ramón y Cajal, Gastroenterology, Madrid, Spain;(10)Hospital Clínico San Carlos, Gastroenterology, Madrid, Spain;(11)H.U. Bellvitge, Gastroenterology, Bellvitge, Spain;(12)Hospital Rio Hortega, Gastroenterology, Valladolid, Spain;(13)Hospital Ernest LLuch, Gastroenterology, Calatayud, Spain;(14)Hospital Álvaro Cunqueiro, Gastroenterology, Vigo, Spain;(15)Hospital de La Princesa, Gastroenterology, Madrid, Spain;(16)Hospital Universitario Miguel SErvet, Gastroenterology, Zaragoza, Spain;(17)H. de la Sta Creu i Sant Pau, Gastroenterology, Barcelona, Spain;(18)H. La Paz, Gastroenterology, Madrid, Spain;(19)Hospital de Sabadell, Gastroenterology, Sabadell, Spain;(20)Hospital de Cruces, Gastroetnerology, Bilbao, Spain;(21)Complejo Asistencial Universitario de León, Gastroenterology, Leon, Spain;(22)H. Del Mar, Gastroenterology, Barcelona, Spain;(23)Hospital General Universitario de Alicante, Gastroenterology, Alicante, Spain;(24)H. Cabueñes, Gastroenterology, Gijon, Spain;(25)Complexo Hospitalario Universitario de Pontevedra, Gastroenterology, Pontevedra, Spain;(26)H. Mútua Terrassa, Gastroenterology, Barcelona, Spain;(27)H. U. Marques de Valdecilla, Gastroenterology, Santander, Spain;(28)H.U. Canarias, Gastroenterology, Tenerife, Spain;(29)Hospital Universitario de Burgos, Gastroenterology, Burgos, Spain;(30)H. General de Ciudad Real, Gastroenterology, Ciudad REal, Spain;(31)H.G.U. Gregorio Marañón, Gastroenterology, Madrid, Spain;(32)Consorci Sanitari de Terrassa, Gastroenterology, Terrasa, Spain;(33)H. Moisès Broggi, Gastroenterology, San JOan Despi, Spain;(34)Complexo H. Universitario de Ourense, Gastroenterology, Ourense, Spain;(35)H. Manises, Gastroenterology, Manises, Spain;(36)H. Nuestra Sra. de la Candelaria, Gastroenterology, Tenerife, Spain;(37)H.G.U. Elche, Gastroenterology, Elche, Spain;(38)H.U. de Santiago, Gastroenterology, Santiago de Compostolea, Spain;(39)Hospital Clínico Universtario Lozano Blesa, Gastroenterology, Zaragoza, Spain;on behalf of the ENEIDA Registry of GETECCU
P411: Early ultrasound assessment predicts therapy response: an easy tool for clinical decision makingECCO’23 CopenhagenYear: 2023
Authors: CalabresePhD, E.(1)*;Castiglione, F.(2);De Cristofaro, E.(1);Rispo, A.(2);Capacchione , C.(1);Testa, A.(2);Guarino, A.D.(2);Caiazzo, A.(2);Monteleone, G.(1);Zorzi, F.(1);
(1)University of Rome Tor Vergata, Gastroenterology Unit- Department of Systems Medicine, Rome, Italy;(2)Federico II- School of Medicine- Naples- Italy, Gastroenterology- Department of Clinical Medicine and Surgery, Naples, Italy;
P412: Time trend in clinicopathological features and prognosis of Ulcerative Colitis associated neoplasia: A nationwide cohort in JapanECCO’23 CopenhagenYear: 2023
Authors: Komatsu, K.(1)*;Shinagawa, T.(1);Noguchi, T.(1);Uchino, M.(2);Ikeuchi, H.(2);Okabayashi, K.(3);Tanaka, S.(4);Futami, K.(5);Itabashi, M.(6);Watanabe, K.(7);Nagahara, H.(8);Okita, Y.(9);Shimada, Y.(10);Mizuuchi, Y.(11);Okamoto, K.(12);Yamada, K.(13);Sato, Y.(14);Mizushima, T.(15);Kimura, H.(16);Takahashi, K.(17);Hida, K.(18);Kinugasa, Y.(19);Ishida, F.(20);Okuda, J.(21);Daito, K.(22);Yamamoto, T.(23);Yamamoto, S.(24);Koyama, F.(25);Hanai, T.(26);Komori, K.(27);Shida, D.(28);Arakaki, J.(29);Akagi, Y.(30);Yamaguchi, S.(31);Ueno, H.(32);Matsuda, K.(33);Ajioka, Y.(34);Sugihara, K.(35);Ishihara, S.(1);
(1)The University of Tokyo, Department of Surgical Oncology, Tokyo, Japan;(2)Hyogo College of Medicine, Department of Inflammatory Bowel Disease Surgery, Nishinomiya, Japan;(3)Keio University School of Medicine, Department of Surgery, Tokyo, Japan;(4)Hiroshima University Hospital, Department of Endoscopy, Hiroshima, Japan;(5)Fukuoka University Chikushi Hospital, Department of Surgery, Chikushino, Japan;(6)Tokyo Women's Medical University, Department of Surgery- Division of Inflammatory Bowel Disease Surgery, Tokyo, Japan;(7)Tohoku University Graduate School of Medicine, Department of Surgery, Sendai, Japan;(8)Osaka City University Graduate School of Medicine, Department of Gastroenterological Surgery, Osaka, Japan;(9)Mie University Graduate School of Medicine, Department of Gastrointestinal and Pediatric Surgery- Institute of Life Sciences, Mie, Japan;(10)Niigata University, Division of Digestive and General Surgery- Graduate School of Medical and Dental Sciences, Niigata, Japan;(11)Kyushu University, Department of Surgery and Oncology- Graduate School of Medical Sciences, Fukuoka, Japan;(12)Tokyo Yamate Medical Center, Department of Coloproctology, Tokyo, Japan;(13)Coloproctology Center Takano Hospital, Department of Surgery, Kumamoto, Japan;(14)Toho University Sakura Medical Center, Department of Surgery, Chiba, Japan;(15)Osaka University, Department of Gastroenterological Surgery- Graduate School of Medical, Osaka, Japan;(16)Yokohama City University Medical Center, Inflammatory Bowel Disease Center, Yokohama, Japan;(17)Tohoku Rosai Hospital, Department of Colorectal Surgery, Sendai, Japan;(18)Kyoto University Hospital, Department of Surgery-, Kyoto, Japan;(19)Tokyo Medical and Dental University, Department of Gastrointestinal Surgery, Tokyo, Japan;(20)Showa University Northern Yokohama Hospital, Digestive disease center, Kanagawa, Japan;(21)Osaka Medical and Pharmaceutical University, Department of General and Gastroenterological Surgery, Takatsuki, Japan;(22)Kindai University, Department of Surgery- Faculty of Medicine, Osaka, Japan;(23)Yokkaichi Hazu Medical Center, Inflammatory Bowel Disease Center, Yokkaichi, Japan;(24)Tokai University School of Medicine, Department of Gastroenterological Surgery, Tokyo, Japan;(25)Nara Medical University, Department of Surgery, Nara, Japan;(26)Fujita Health University- School of Medicine, Department of Surgery, Mie, Japan;(27)Aichi Cancer Center Hospital, Department of Gastroenterological Surgery, Aichi, Japan;(28)IMSUT Hospital- The Institute of Medical Science- The University of Tokyo, Department of Surgery, Tokyo, Japan;(29)Urasoe General Hospital, Center for Gastroenterology- Department of Surgery, Okinawa, Japan;(30)Kurume University Hospital, Department of Surgery, Kurume, Japan;(31)Saitama Medical University International Medical Center-, Department of Gastroenterological Surgery, Saitama, Japan;(32)National Defense Medical College, Department of Surgery, Tokorozawa, Japan;(33)Teikyo University School of Medicine, Department of Surgery, Tokyo, Japan;(34)Niigata University, Department of Pathology, Niigata, Japan;(35)Tokyo Medical and Dental University, Honorary Director, Tokyo, Japan;The Study Group for Inflammatory Bowel Disease Associated Intestinal Cancers by the Japanese Society for Cancer of the Colon and Rectum
P413: Withdrawal versus continuation of thiopurine in vedolizumab-treated patients with Ulcerative Colitis (VIEWS): a multi-centre randomised controlled trialECCO’23 CopenhagenYear: 2023
Authors: Pudipeddi, A.(1)*;Paramsothy, S.(1);Kariyawasam, V.(2);Paramsothy, R.(2);Ghaly, S.(3);Haifer, C.(3);An, Y.K.(4);Begun, J.(4);Connor, S.(5);Corte, C.(6);Ward, M.(7);De Cruz, P.(8);Fung, C.(9);Redmond, D.(1);Leong, R.W.(1);
(1)Concord Repatriation General Hospital, Department of Gastroenterology and Hepatology, Sydney, Australia;(2)Blacktown Hospital, Department of Gastroenterology, Sydney, Australia;(3)St Vincent's Hospital, Department of Gastroenterology, Sydney, Australia;(4)Mater Hospital, Department of Gastroenterology, Brisbane, Australia;(5)Liverpool Hospital, Department of Gastroenterology, Sydney, Australia;(6)Royal Prince Alfred Hospital, AW Morrow Gastroenterology and Liver Centre, Sydney, Australia;(7)The Alfred Hospital, Department of Gastroenterology, Melbourne, Australia;(8)Austin Hospital, Department of Gastroenterology, Melbourne, Australia;(9)Concord Repatriation General Hospital, Department of Anatomical Pathology, Sydney, Australia;
P414: Comparative real-world effectiveness and persistence of vedolizumab versus anti-TNF therapy in biologic-naïve patients with Crohn´s disease with propensity score adjustment: two-year maintenance phase results from the prospective VEDO-IBD studyECCO’23 CopenhagenYear: 2023
Authors: Bokemeyer, B.(1,2,3)*;Plachta-Danielzik, S.(3);Efken, P.(4);Mohl, W.(5);Hoffstadt, M.(6);Krause, T.(7);Schweitzer, A.(8);Schnoy, E.(9);Atreya, R.(10);Teich, N.(11);Trentmann, L.(12);Ehehalt, R.(13);Franzenburg, S.(3);Hartmann, P.(4);di Giuseppe, R.(3);Schreiber, S.(2,3);
(1)Interdisciplinary Crohn Colitis Centre Minden, Crohn Colitis Centre, Minden, Germany;(2)University Hospital Schleswig-Holstein- Campus Kiel, Clinic of General Internal Medicine I, Kiel, Germany;(3)Competence network IBD, Study department, Kiel, Germany;(4)Gastroenterology Practice Minden, Practice, Minden, Germany;(5)Center for Gastroenterology Saar MVZ, Practice, Saarbruecken, Germany;(6)Gastroenterology Practice Iserlohn, Practice, Iserlohn, Germany;(7)Gastroenterology Practice Kassel, Practice, Kassel, Germany;(8)Gastroenterology Practice Muenster, Practice, Muenster, Germany;(9)University Hospital Augsburg, III. medical clinic, Augsburg, Germany;(10)Friedrich-Alexander-University Erlangen-Nuernberg, Medical Clinic 1, Erlangen, Germany;(11)Gastroenterology Practice Leipzig, Practice, Leipzig, Germany;(12)Gastroenterology Practice Bremen, Practice, Bremen, Germany;(13)Gastroenterology Practice Heidelberg, Practice, Heidelberg, Germany;
P415: Real-world data in Inflammatory Bowel Diseases on vedolizumab therapy: Interim analysis of the non-interventional LISTEN II studyECCO’23 CopenhagenYear: 2023
Authors: Stallmach, A.(1)*;Schulze, H.(2);Teich, N.(3);Cavlar, T.(4);Jana, K.(4);Henneberger, S.(5);
(1)University Hospital Jena, Clinic for Internal Medicine IV, Jena, Germany;(2)AGAPLESION Markus-Hospital, Medical Clinic I, Frankfurt am Main, Germany;(3)Group Practice in Internal Medicine for Digestive and Metabolic Diseases, Group Practice in Internal Medicine for Digestive and Metabolic Diseases, Leipzig, Germany;(4)Takeda Pharma Vertrieb GmbH & Co. KG, Medical Department, Berlin, Germany;(5)Institut Dr. Schauerte GmbH, Project Management, Munich, Germany;
P416: The impact of remission on healthcare resource utilisation and costs amongst patients with inflammatory bowel disease in France, Germany, Italy, Spain, and the United Kingdom.ECCO’23 CopenhagenYear: 2023
Authors: Patel, K.V.(1)*;Salmon, P.(2);Marin-Jiménez, I.(3);Thessen, M.(4);Kligys, K.(4);Sharma, D.(4);Sanchez Gonzalez, Y.(4);Kershaw, J.(5);
(1)NHS Foundation Trust, St George's University Hospital, London, United Kingdom;(2)Adelphi Real World, n/a, Bollington, United Kingdom;(3)Hospital General Universitario Gregorio Marañón, n/a, Madrid, Spain;(4)AbbVie Inc, n/a, North Chicago, United States;(5)Adelphi Real World, n/a, Bollington, United States;
P417: Frequent Early Nocebo Complaints but Maintained Clinical Efficacy, Biomarker and Therapeutic drug levels following mandatory Biosimilar Switch in Patients with Inflammatory Bowel disease: Preliminary data from a Prospective Observational Cohort StudyECCO’23 CopenhagenYear: 2023
Authors: Wetwittayakhlang, P.(1)*;Karkout, K.(2);Tselekouni, P.(1);Aljabri, R.(1);Bessissow, T.(1);Afif, W.(1);Wild, G.(1);Bitton, A.(1);LakatosPhD, P.L.(3,4);
(1)McGill University Health Centre, Division of Gastroenterology and Hepatology, Montreal, Canada;(2)McGill University Health Centre, Department of Internal Medicine, Montreal, Canada;(3)Mcgill University Health Center, IBD Centre, Montréal, Canada;(4)Semmelweis University, Department of Internal Medicine and Oncology, Budapest, Hungary;